探索药物重用治疗抑郁症的潜力
Chaitenya Verma1, Kritika Jain2, Ashok Saini2
1Department of Pathology, Ohio State University, Columbus, OH, United States.
Progress in molecular biology and translational science
|June 28, 2024
概括
药物再利用通过探索现有药物,为治疗耐药抑郁症提供了新的希望. 进一步研究抑郁症的研究.
科学领域:
- 药理学和精神病学 药理学和精神病学
- 药物发现和开发 药物发现和开发
背景情况:
- 药物开发成本不断上升和创新速度缓慢,推动了对药物重新用途的兴趣.
- 传统的研究依赖于实验数据和非标签药物使用的治疗策略.
- 新出现的证据表明,抑郁症不仅涉及神经递质失衡,包括炎症,血流减少和神经毒素.
研究的目的:
- 探索治疗替代方案并评估抑郁症药物重新定位的有效性.
- 根据新的抑郁机制,识别潜在的药物候选人进行重新利用.
主要方法:
- 审查现有的关于抑郁症药物再利用的文献.
- 研究非典型抗精神病药物,中枢神经系统兴奋剂和神经递质对抗剂的疗效.
- 对实验研究和非标签药物使用数据的分析.
主要成果:
- 药物重新定位在治疗耐治疗抑郁症方面表现有前途.
- 目前正在研究几个药物类别,包括非典型抗精神病药物,中枢神经系统刺激剂和神经递质对抗剂.
- 重新定位的努力是通过对抑郁症潜在机制的更广泛理解来告知的.
结论:
- 药物重新定位是解决抑郁症新药开发局限性的可行策略.
- 进一步进行全面的研究是必要的,以验证重新用途药物的配方,疗效和监管批准.
- 了解各种抑郁机制是成功制药重定向的关键.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
215
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
215
Antidepressant Drugs: Overview
433
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
433
Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
363
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
363
G-protein Coupled Receptors
118.0K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
118.0K
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K


